As of December 31, 2022, the Company had RMB1,458.2 million in cash and cash equivalents and short-term investments.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on GRCL:
- Gracell Biotechnologies Reports Fourth Quarter and Full Year 2022 Unaudited Financial Results, and Provides Corporate Update
- Gracell management to meet virtually with Jefferies
- Gracell Biotechnologies to Participate in Two Upcoming Investor Conferences
- Gracell: China’s NMPA clears IND application for GC012F
- Gracell: FDA clears IND application for Phase 1b/2 FasTCAR-T GC012F trial